Europe Takes Action to Foster Advanced Therapy Development

News
Article

The European Commission and EMA have created an action plan to address challenges identified by stakeholders involved in developing advanced therapies.

On Oct. 20, 2017, the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA) published a joint action plan to help further the development of advanced therapy medicinal products (ATMPs). The plan includes new guidelines, training sessions, and harmonization efforts, which will help streamline procedures and address requirements and challenges associated with these products.

The plan, developed in association with European Member States, includes 19 actions that address early interaction, information sharing, harmonization between Member States, and problems with patient access. A GMP guideline will address manufacturing requirements for ATMPs. Other guidelines will clarify regulatory expectations on ATMPs and investigational ATMPs. Training sessions will also be organized by EMA.

ATMPs are developed using genes or cells and are often ground-breaking treatments for severe, untreatable, or chronic diseases that do not have conventional treatment options. Nine such products have been approved in Europe since ATMP regulations were adopted in 2009, and 18 marketing authorization applications have been received by EMA. International regulatory agencies, including FDA, Health Canada, and the Japanese Pharmaceuticals and Medical Devices Agency, have worked together to share their ATMP experiences in order to foster the development of these products.

Source: EMA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.